A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension
Source · ClinicalTrials.gov: elamipretide
TLDR
ClinicalTrials.gov lists a phase 3 trial of elamipretide for primary mitochondrial myopathy as terminated. The multicenter study was designed to evaluate safety and efficacy against placebo, with a planned open-label extension; the excerpt provides no results or reason for termination.
- 01The registry reports the trial status as terminated.
- 02The study used a randomized, double-blind, parallel-group, placebo-controlled design.
- 03An open-label treatment extension was planned.
Why it matters Editorial
The termination status is relevant to elamipretide’s clinical development, but the excerpt does not establish any safety or efficacy findings.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide